Savings from the introduction of BPaL and BPaLM regimens at the country level
BACKGROUND: In 2022, the WHO recommended the 6-month regimens BPaL (bedaquiline + pretomanid + linezolid) and BPaLM (BPaL + moxifloxacin) as treatment options for most forms of drug-resistant TB. SLASH-TB estimates the cost-saving and cost-effectiveness for the healthcare system and patients when a...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
International Union Against Tuberculosis and Lung Disease (The Union)
2024-07-01
|
| Series: | IJTLD Open |
| Subjects: | |
| Online Access: | https://www.ingentaconnect.com/contentone/iuatld/ijtldo/2024/00000001/00000007/art00006 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832591382673358848 |
|---|---|
| author | C. Auer A. Gupta C. Malbacius A. Ghafoor Y. Kock O. Medvedieva P. Hanlon P. Steinmann S. Juneja |
| author_facet | C. Auer A. Gupta C. Malbacius A. Ghafoor Y. Kock O. Medvedieva P. Hanlon P. Steinmann S. Juneja |
| author_sort | C. Auer |
| collection | DOAJ |
| description | BACKGROUND: In 2022, the WHO recommended the 6-month regimens BPaL (bedaquiline + pretomanid + linezolid) and BPaLM (BPaL + moxifloxacin) as treatment options for most forms of drug-resistant TB. SLASH-TB estimates the cost-saving and cost-effectiveness for the healthcare system and patients when a country switches from current standard-of-care treatment regimens to BPaL/BPaLM. METHODOLOGY: Country data from national TB programmes (NTP) are used to calculate the costs for all regimens and treatment outcomes. Where BPaL/BPaLM is not currently used, clinical trial outcomes data are used to estimate cost-effectiveness. DALYs are calculated using the Global Burden of Disease (GBD) database. RESULTS: We present the results of four countries that have used the tool and shared their data. When shorter and longer regimens are replaced with BPaL/BPaLM, the savings per patient treated in Pakistan, the Philippines, South Africa, and Ukraine are $746, $478, $757, and $2,636, respectively. An increased number of patients would be successfully treated with BPaL/BPaLM regimens, with 411, 1,025, 1,371 and 829 lives saved and 20,179, 27,443, 33,384 and 21,924 DALYs averted annually in the four countries, respectively. CONCLUSION: Through BPaL/BPaLM regimens, drug-resistant TB treatment has become more effective, shorter, less burdensome for patients, cheaper for both health systems and patients, and saves more lives. |
| format | Article |
| id | doaj-art-846fa0b3abda4a4da43bfc0f8f7195f4 |
| institution | Kabale University |
| issn | 3005-7590 |
| language | English |
| publishDate | 2024-07-01 |
| publisher | International Union Against Tuberculosis and Lung Disease (The Union) |
| record_format | Article |
| series | IJTLD Open |
| spelling | doaj-art-846fa0b3abda4a4da43bfc0f8f7195f42025-01-22T12:12:38ZengInternational Union Against Tuberculosis and Lung Disease (The Union)IJTLD Open3005-75902024-07-011731431910.5588/ijtldopen.24.02136Savings from the introduction of BPaL and BPaLM regimens at the country levelC. Auer0A. Gupta1C. Malbacius2A. Ghafoor3Y. Kock4O. Medvedieva5P. Hanlon6P. Steinmann7S. Juneja8Swiss Tropical and Public Health Institute, Allschwil, Switzerland;TB Alliance, New York, NY, USA;Disease Prevention and Control Bureau, Department of Health, Manila, The Philippines;National Tuberculosis Program, Islamabad, Pakistan;National Department of Health, Pretoria, South Africa;Public Health Center, Ministry of Health, Kyiv, UkraineSwiss Tropical and Public Health Institute, Allschwil, Switzerland;Swiss Tropical and Public Health Institute, Allschwil, Switzerland;TB Alliance, New York, NY, USA;BACKGROUND: In 2022, the WHO recommended the 6-month regimens BPaL (bedaquiline + pretomanid + linezolid) and BPaLM (BPaL + moxifloxacin) as treatment options for most forms of drug-resistant TB. SLASH-TB estimates the cost-saving and cost-effectiveness for the healthcare system and patients when a country switches from current standard-of-care treatment regimens to BPaL/BPaLM. METHODOLOGY: Country data from national TB programmes (NTP) are used to calculate the costs for all regimens and treatment outcomes. Where BPaL/BPaLM is not currently used, clinical trial outcomes data are used to estimate cost-effectiveness. DALYs are calculated using the Global Burden of Disease (GBD) database. RESULTS: We present the results of four countries that have used the tool and shared their data. When shorter and longer regimens are replaced with BPaL/BPaLM, the savings per patient treated in Pakistan, the Philippines, South Africa, and Ukraine are $746, $478, $757, and $2,636, respectively. An increased number of patients would be successfully treated with BPaL/BPaLM regimens, with 411, 1,025, 1,371 and 829 lives saved and 20,179, 27,443, 33,384 and 21,924 DALYs averted annually in the four countries, respectively. CONCLUSION: Through BPaL/BPaLM regimens, drug-resistant TB treatment has become more effective, shorter, less burdensome for patients, cheaper for both health systems and patients, and saves more lives.https://www.ingentaconnect.com/contentone/iuatld/ijtldo/2024/00000001/00000007/art00006drug-resistant tb treatmentsix-month regimenscost savingsbedaquilinepretomanideconomic evaluationcost analysis |
| spellingShingle | C. Auer A. Gupta C. Malbacius A. Ghafoor Y. Kock O. Medvedieva P. Hanlon P. Steinmann S. Juneja Savings from the introduction of BPaL and BPaLM regimens at the country level IJTLD Open drug-resistant tb treatment six-month regimens cost savings bedaquiline pretomanid economic evaluation cost analysis |
| title | Savings from the introduction of BPaL and BPaLM regimens at the country level |
| title_full | Savings from the introduction of BPaL and BPaLM regimens at the country level |
| title_fullStr | Savings from the introduction of BPaL and BPaLM regimens at the country level |
| title_full_unstemmed | Savings from the introduction of BPaL and BPaLM regimens at the country level |
| title_short | Savings from the introduction of BPaL and BPaLM regimens at the country level |
| title_sort | savings from the introduction of bpal and bpalm regimens at the country level |
| topic | drug-resistant tb treatment six-month regimens cost savings bedaquiline pretomanid economic evaluation cost analysis |
| url | https://www.ingentaconnect.com/contentone/iuatld/ijtldo/2024/00000001/00000007/art00006 |
| work_keys_str_mv | AT cauer savingsfromtheintroductionofbpalandbpalmregimensatthecountrylevel AT agupta savingsfromtheintroductionofbpalandbpalmregimensatthecountrylevel AT cmalbacius savingsfromtheintroductionofbpalandbpalmregimensatthecountrylevel AT aghafoor savingsfromtheintroductionofbpalandbpalmregimensatthecountrylevel AT ykock savingsfromtheintroductionofbpalandbpalmregimensatthecountrylevel AT omedvedieva savingsfromtheintroductionofbpalandbpalmregimensatthecountrylevel AT phanlon savingsfromtheintroductionofbpalandbpalmregimensatthecountrylevel AT psteinmann savingsfromtheintroductionofbpalandbpalmregimensatthecountrylevel AT sjuneja savingsfromtheintroductionofbpalandbpalmregimensatthecountrylevel |